NASDAQ:CDAK

Codiak BioSciences Competitors

$13.89
+0.23 (+1.68 %)
(As of 04/14/2021 04:30 PM ET)
Add
Compare
Today's Range
$13.50
Now: $13.89
$15.18
50-Day Range
$13.40
MA: $15.91
$18.68
52-Week Range
$7.90
Now: $13.89
$37.85
Volume274,261 shs
Average Volume150,004 shs
Market Capitalization$305.50 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Codiak BioSciences (NASDAQ:CDAK) Vs. ATRA, FMTX, MESO, CRTX, CRIS, and CHRS

Should you be buying CDAK stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Codiak BioSciences, including Atara Biotherapeutics (ATRA), Forma Therapeutics (FMTX), Mesoblast (MESO), Cortexyme (CRTX), Curis (CRIS), and Coherus BioSciences (CHRS).

Atara Biotherapeutics (NASDAQ:ATRA) and Codiak BioSciences (NASDAQ:CDAK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Valuation & Earnings

This table compares Atara Biotherapeutics and Codiak BioSciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atara BiotherapeuticsN/AN/A$-290,980,000.00($5.67)-2.44
Codiak BioSciencesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and target prices for Atara Biotherapeutics and Codiak BioSciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atara Biotherapeutics03702.70
Codiak BioSciences00303.00

Atara Biotherapeutics presently has a consensus target price of $35.8750, suggesting a potential upside of 159.03%. Codiak BioSciences has a consensus target price of $30.00, suggesting a potential upside of 115.98%. Given Atara Biotherapeutics' higher probable upside, analysts plainly believe Atara Biotherapeutics is more favorable than Codiak BioSciences.

Profitability

This table compares Atara Biotherapeutics and Codiak BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atara BiotherapeuticsN/A-94.86%-82.17%
Codiak BioSciencesN/AN/AN/A

Summary

Codiak BioSciences beats Atara Biotherapeutics on 3 of the 5 factors compared between the two stocks.

Codiak BioSciences (NASDAQ:CDAK) and Forma Therapeutics (NASDAQ:FMTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Codiak BioSciences and Forma Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codiak BioSciencesN/AN/AN/AN/AN/A
Forma Therapeutics$100.56 million11.45$-34,790,000.00N/AN/A

Codiak BioSciences has higher earnings, but lower revenue than Forma Therapeutics.

Profitability

This table compares Codiak BioSciences and Forma Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Codiak BioSciencesN/AN/AN/A
Forma TherapeuticsN/A-29.54%-20.61%

Institutional & Insider Ownership

67.3% of Forma Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Codiak BioSciences and Forma Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Codiak BioSciences00303.00
Forma Therapeutics00603.00

Codiak BioSciences currently has a consensus target price of $30.00, indicating a potential upside of 115.98%. Forma Therapeutics has a consensus target price of $61.6667, indicating a potential upside of 120.55%. Given Forma Therapeutics' higher probable upside, analysts plainly believe Forma Therapeutics is more favorable than Codiak BioSciences.

Summary

Forma Therapeutics beats Codiak BioSciences on 4 of the 6 factors compared between the two stocks.

Codiak BioSciences (NASDAQ:CDAK) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Earnings & Valuation

This table compares Codiak BioSciences and Mesoblast's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codiak BioSciencesN/AN/AN/AN/AN/A
Mesoblast$32.16 million35.10$-77,940,000.00($0.74)-11.76

Codiak BioSciences has higher earnings, but lower revenue than Mesoblast.

Profitability

This table compares Codiak BioSciences and Mesoblast's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Codiak BioSciencesN/AN/AN/A
Mesoblast-591.00%-18.69%-13.85%

Insider & Institutional Ownership

2.8% of Mesoblast shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Codiak BioSciences and Mesoblast, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Codiak BioSciences00303.00
Mesoblast12302.33

Codiak BioSciences currently has a consensus price target of $30.00, suggesting a potential upside of 115.98%. Mesoblast has a consensus price target of $14.55, suggesting a potential upside of 67.24%. Given Codiak BioSciences' stronger consensus rating and higher probable upside, analysts plainly believe Codiak BioSciences is more favorable than Mesoblast.

Summary

Codiak BioSciences beats Mesoblast on 5 of the 8 factors compared between the two stocks.

Codiak BioSciences (NASDAQ:CDAK) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Institutional and Insider Ownership

55.5% of Cortexyme shares are owned by institutional investors. 19.8% of Cortexyme shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Codiak BioSciences and Cortexyme, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Codiak BioSciences00303.00
Cortexyme21402.29

Codiak BioSciences presently has a consensus target price of $30.00, suggesting a potential upside of 115.98%. Cortexyme has a consensus target price of $50.00, suggesting a potential upside of 37.36%. Given Codiak BioSciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Codiak BioSciences is more favorable than Cortexyme.

Profitability

This table compares Codiak BioSciences and Cortexyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Codiak BioSciencesN/AN/AN/A
CortexymeN/A-37.78%-35.24%

Earnings & Valuation

This table compares Codiak BioSciences and Cortexyme's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codiak BioSciencesN/AN/AN/AN/AN/A
CortexymeN/AN/A$-36,980,000.00($1.94)-18.76

Summary

Codiak BioSciences beats Cortexyme on 4 of the 7 factors compared between the two stocks.

Codiak BioSciences (NASDAQ:CDAK) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.

Valuation and Earnings

This table compares Codiak BioSciences and Curis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codiak BioSciencesN/AN/AN/AN/AN/A
Curis$10 million108.63$-32,140,000.00($0.86)-13.80

Codiak BioSciences has higher earnings, but lower revenue than Curis.

Analyst Recommendations

This is a summary of recent ratings for Codiak BioSciences and Curis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Codiak BioSciences00303.00
Curis00503.00

Codiak BioSciences currently has a consensus target price of $30.00, suggesting a potential upside of 115.98%. Curis has a consensus target price of $14.60, suggesting a potential upside of 23.00%. Given Codiak BioSciences' higher probable upside, analysts clearly believe Codiak BioSciences is more favorable than Curis.

Institutional & Insider Ownership

34.7% of Curis shares are held by institutional investors. 7.3% of Curis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Codiak BioSciences and Curis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Codiak BioSciencesN/AN/AN/A
Curis-279.33%N/A-81.32%

Summary

Curis beats Codiak BioSciences on 4 of the 7 factors compared between the two stocks.

Coherus BioSciences (NASDAQ:CHRS) and Codiak BioSciences (NASDAQ:CDAK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Valuation and Earnings

This table compares Coherus BioSciences and Codiak BioSciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coherus BioSciences$356.07 million2.83$89.83 million$1.2311.27
Codiak BioSciencesN/AN/AN/AN/AN/A

Coherus BioSciences has higher revenue and earnings than Codiak BioSciences.

Analyst Recommendations

This is a breakdown of current ratings for Coherus BioSciences and Codiak BioSciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Coherus BioSciences01402.80
Codiak BioSciences00303.00

Coherus BioSciences presently has a consensus target price of $26.50, indicating a potential upside of 91.20%. Codiak BioSciences has a consensus target price of $30.00, indicating a potential upside of 115.98%. Given Codiak BioSciences' stronger consensus rating and higher probable upside, analysts plainly believe Codiak BioSciences is more favorable than Coherus BioSciences.

Profitability

This table compares Coherus BioSciences and Codiak BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Coherus BioSciences33.06%90.98%27.33%
Codiak BioSciencesN/AN/AN/A

Summary

Coherus BioSciences beats Codiak BioSciences on 5 of the 7 factors compared between the two stocks.


Codiak BioSciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.85+0.4%$1.16 billionN/A-3.00
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$27.96+0.9%$1.14 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.70+0.7%$1.12 billion$32.16 million-9.89Analyst Upgrade
Decrease in Short Interest
News Coverage
Cortexyme logo
CRTX
Cortexyme
1.3$36.40+2.0%$1.05 billionN/A-15.17Analyst Downgrade
Curis logo
CRIS
Curis
1.1$11.87+4.2%$1.04 billion$10 million-14.48Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$13.86+0.4%$1.01 billion$356.07 million6.79Unusual Options Activity
News Coverage
Vaxcyte logo
PCVX
Vaxcyte
1.7$19.90+3.3%$988.06 millionN/A0.00Increase in Short Interest
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.04+5.7%$970.33 million$20.49 million-12.46Increase in Short Interest
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$24.83+2.7%$921.52 millionN/A-4.10Insider Selling
Increase in Short Interest
News Coverage
Passage Bio logo
PASG
Passage Bio
1.8$16.63+5.2%$895.21 millionN/A0.00Increase in Short Interest
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$9.17+1.6%$882.12 million$250,000.00-7.22Analyst Upgrade
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$19.92+3.9%$878.83 million$42.74 million-221.33Increase in Short Interest
News Coverage
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$25.57+9.0%$878.32 millionN/A0.00Analyst Report
News Coverage
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.34+1.7%$875.47 million$69.89 million-4.38
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$23.45+5.2%$848.17 millionN/A-9.69Analyst Report
Increase in Short Interest
Inhibrx logo
INBX
Inhibrx
1.6$20.82+7.0%$840.65 millionN/A0.00Decrease in Short Interest
News Coverage
Cellectis logo
CLLS
Cellectis
1.3$19.51+0.4%$831.22 million$22.99 million-10.38
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.46+3.1%$823.81 million$2.51 million-3.92
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$5.04+0.6%$788.22 million$1.12 million-5.09Increase in Short Interest
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.58+4.5%$785.75 millionN/A0.00Lockup Expiration
Gap Up
Vaxart logo
VXRT
Vaxart
1.3$5.48+0.7%$650.07 million$9.86 million-9.29
DBV Technologies logo
DBVT
DBV Technologies
1.0$6.45+8.7%$647.15 million$14.75 million-2.77Increase in Short Interest
Gap Down
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$20.60+3.6%$643.68 million$5.78 million-9.67Insider Selling
Increase in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.3$30.35+1.4%$631.08 millionN/A0.00Lockup Expiration
News Coverage
Athira Pharma logo
ATHA
Athira Pharma
2.2$17.49+3.4%$627.33 millionN/A0.00Analyst Upgrade
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.70+0.7%$601.99 million$13.29 million-9.72
Compugen logo
CGEN
Compugen
1.4$8.66+0.7%$596.62 million$17.80 million-23.40Analyst Report
News Coverage
Agenus logo
AGEN
Agenus
1.6$2.69+0.7%$554.70 million$150.05 million-2.47News Coverage
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$9.09+2.0%$553.38 millionN/A-1.33
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$21.19+0.9%$544.11 millionN/A-6.11
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$5.30+6.6%$529.05 millionN/A-2.57Increase in Short Interest
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.71+1.6%$496.35 million$22.24 million-4.33Increase in Short Interest
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.21+1.7%$454.86 millionN/A-8.14Increase in Short Interest
AVROBIO logo
AVRO
AVROBIO
1.7$11.21+5.0%$443.27 millionN/A-3.40
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$12.05+0.9%$436.22 millionN/A0.00Analyst Report
Opthea logo
OPT
Opthea
1.5$9.65+3.4%$433.70 millionN/A0.00Lockup Expiration
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$8.57+3.3%$433.23 million$4.36 million-3.00Analyst Downgrade
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$9.77+5.3%$419.89 million$147.87 million-3.25
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$9.17+0.8%$380.79 millionN/A0.00Analyst Report
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.06+0.2%$363.15 millionN/A0.00
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.87+8.6%$352.42 million$8.15 million-1.50Increase in Short Interest
News Coverage
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.38+1.6%$340.45 million$96.12 million-12.88
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$8.80+2.7%$321.45 million$250,000.00-3.14Analyst Upgrade
Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.4$7.34+1.2%$302.53 million$15.36 million-11.12Analyst Report
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$5.60+0.9%$290.52 million$2.91 million-1.95
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.57+3.3%$281.04 millionN/A-3.53News Coverage
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.88+1.1%$265.61 million$4.13 million-4.18
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$11.25+3.6%$261.08 millionN/A-8.21
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.72+0.6%$207.38 million$29.35 million-2.00
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$6.70+4.5%$204.97 millionN/A-4.19Gap Down
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.